{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.3","upperLimit":"3.3","value":"3.30"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"13.0","value":"1.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.","dispersionType":"Full Range","groups":[{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"MEDIAN","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102. This outcome measure is applicable for Cohort 4 and 5. Here, Overall Number of Participants Analyzed = participants with PR or better as a best overall response.","reportingStatus":"POSTED","timeFrame":"Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)","title":"Phase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS)","type":"SECONDARY","unitOfMeasure":"Months"}